Efficacy and Safety of Chemotherapy Following Anti-PD-1 Antibody Therapy for Gastric Cancer: A Case of Sclerosing Cholangitis.
Adenocarcinoma
/ drug therapy
Albumins
/ administration & dosage
Antibodies, Monoclonal
/ administration & dosage
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Cholangitis, Sclerosing
/ chemically induced
Female
Humans
Immunotherapy
/ adverse effects
Middle Aged
Nivolumab
/ administration & dosage
Paclitaxel
/ administration & dosage
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Stomach Neoplasms
/ drug therapy
Ramucirumab
cholecystitis
immune checkpoint
nab-paclitaxel
nivolumab
ramucirumab
Journal
Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241
Informations de publication
Date de publication:
01 May 2019
01 May 2019
Historique:
pubmed:
11
1
2019
medline:
10
7
2019
entrez:
11
1
2019
Statut:
ppublish
Résumé
Immunotherapy targeting programmed cell death-1 (PD-1) signaling is becoming the standard of care for advanced gastric cancer. We herein report a patient with gastric adenocarcinoma with peritoneal dissemination who was treated with nab-paclitaxel and ramucirumab following nivolumab and developed sclerosing cholangitis. Endoscopic retrograde cholangiography showed irregular narrowing and widening of the entire intrahepatic biliary system. Intriguingly, the patient receiving second-line chemotherapy with nab-paclitaxel plus ramucirumab prior to being administered nivolumab, however, he had experienced progressive disease. Thereafter, the administration of fourth-line chemotherapy with nab-paclitaxel and ramucirumab following nivolumab resulted in a clinical response. Nivolumab may enhance the efficacy of the subsequent chemotherapy regimens but also induce sclerosing cholangitis.
Identifiants
pubmed: 30626829
doi: 10.2169/internalmedicine.1981-18
pmc: PMC6543221
doi:
Substances chimiques
130-nm albumin-bound paclitaxel
0
Albumins
0
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Nivolumab
31YO63LBSN
Paclitaxel
P88XT4IS4D
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1263-1266Commentaires et corrections
Type : CommentIn
Références
J Clin Oncol. 2005 Sep 1;23(25):6043-53
pubmed: 16087944
Hepatology. 2006 Nov;44(5):1063-74
pubmed: 17058222
Oncologist. 2007 Jul;12(7):864-72
pubmed: 17673617
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6681-8
pubmed: 17982122
Endoscopy. 2008 Mar;40(3):214-8
pubmed: 18264887
Dig Liver Dis. 2009 Jan;41(1):72-7
pubmed: 18294938
Am J Med. 1990 Jul;89(1):73-80
pubmed: 2195892
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
J Transl Med. 2014 May 07;12:116
pubmed: 24885479
Ann Oncol. 2016 Jul;27(7):1304-11
pubmed: 27059553
Oncol Lett. 2016 Jul;12(1):727-730
pubmed: 27347207
Ann Oncol. 2017 Mar 1;28(3):671-672
pubmed: 27993797
Front Pharmacol. 2017 Feb 08;8:49
pubmed: 28228726
Invest New Drugs. 2017 Aug;35(4):529-536
pubmed: 28317087
Invest New Drugs. 2018 Feb;36(1):144-146
pubmed: 28631096
Cancer Immunol Immunother. 2018 Jan;67(1):61-65
pubmed: 28913619
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052
Lancet. 1988 Aug 6;2(8606):302-5
pubmed: 2899720
J Thorac Oncol. 2018 Jan;13(1):106-111
pubmed: 29101058
Eur J Cancer. 2017 Dec;87:65-74
pubmed: 29126088
Oral Oncol. 2018 May;80:100-102
pubmed: 29605290
Endoscopy. 2018 Sep;50(9):E259-E261
pubmed: 29969801
Mayo Clin Proc. 1998 Apr;73(4):380-5
pubmed: 9559044